Regenerating proteins and their expression, regulation, and signaling

Autor: Parikh Abhirath, Stephan Anne-Fleur, Tzanakakis Emmanuel S.

Publikováno v: Biomolecular Concepts, Vol 3, Iss 1, Pp 57-70 (2012)

The regenerating (Reg) protein family comprises C-type lectin-like proteins discovered independently during pancreatitis and pancreatic islet regeneration. However, an increasing number of studies provide evidence of participation of Reg proteins in

Externí odkaz: https://doaj.org/article/8e20ab8e3a3349a8abf3230d80a38409

Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.

Autor: Qin Q; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Jun T; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Wang B; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Patel VG; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Mellgard G; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Zhong X; Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gogerly-Moragoda M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parikh AB; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH, USA., Leiter A; Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gallagher EJ; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA.; Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Alerasool P; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA.; New York Medical College, Valhalla, NY, USA., Garcia P; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Joshi H, Mbbs; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA.; Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Galsky M; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Oh WK; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA., Tsao CK; Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, Third Floor Admin Suite #108 (Hess Building), New York, NY, USA. che-kai.tsao@mssm.edu.

Publikováno v: Discover. Oncology [Discov Oncol] 2022 Aug 12; Vol. 13 (1), pp. 73. Date of Electronic Publication: 2022 Aug 12.

Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.

Autor: Yang Y; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Mori SV; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Li M; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Hinkley M; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Parikh AB; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Collier KA; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Miah A; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Yin M; Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA.

Publikováno v: Cancer medicine [Cancer Med] 2022 Apr; Vol. 11 (7), pp. 1669-1677. Date of Electronic Publication: 2022 Feb 09.

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.

Autor: Patel SH; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., George TL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Wang TF; Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio.; Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Canada., Vogt SM; Department of Pharmacy, The Ohio State University James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio., Folefac E; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Xu M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Yang Y; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Parikh AB; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Verschraegen CF; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Clinton SK; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio., Yin M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio.

Publikováno v: Cancer [Cancer] 2021 Mar 15; Vol. 127 (6), pp. 938-945. Date of Electronic Publication: 2020 Nov 20.

On the Transition to Attendinghood.

Autor: Parikh AB; Genitourinary Oncology Section, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, B406 Starling-Loving Hall, 320 W 10th Avenue, Columbus, OH, 43210, USA. anish.parikh@osumc.edu.

Publikováno v: Journal of cancer education : the official journal of the American Association for Cancer Education [J Cancer Educ] 2021 Feb; Vol. 36 (1), pp. 207-209.